絞り込み

17307

広告

Dynamic changes of CSF sTREM2 in preclinical Alzheimer's disease: the CABLE study.

著者 Ma LZ , Tan L , Bi YL , Shen XN , Xu W , Ma YH , Li HQ , Dong Q , Yu JT
Mol Neurodegener.2020 Apr 10 ; 15(1):25.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Loss of function of triggering receptor expressed on myeloid cell 2 (TREM2), a key receptor selectively expressed by microglia in the brain, contributes to the development of Alzheimer's disease (AD). Whether TREM2 levels are pathologically altered during the preclinical phase, and whether cerebrospinal fluid (CSF) soluble TREM2 protein (sTREM2) has a relationship with major pathological processes including Aβ and tau deposition are still unclear.
PMID: 32276587 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード